France Buprenorphine and Naloxone Market Insight
Published: 26 June 2026 | Report Format: Electronic (PDF) | Author: Aditi and Govind
France Buprenorphine and Naloxone Market will grow at a rate of 5.12% due to rising demand for opioid use disorder (OUD) maintenance therapies, public healthcare rehabilitation automation, the specialized addiction treatment sector
France Buprenorphine and Naloxone Market Insights Forecasts to 2035
- The France Buprenorphine and Naloxone Market Size Was Estimated USD 78.5 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.12% from 2025 to 2035
- The France Buprenorphine and Naloxone Market Size is Expected to rise around USD 129.3 Million by 2035
Notable Insights for the France Buprenorphine and Naloxone Market
- Segmentation on the basis of Product Type indicates that Sublingual Films and combination tablets dominate France market in 2025 with 62.4% share across specialized addiction centers.
- Segmentation on the basis of Application indicates that Hospitals, Outpatient Clinics and Rehabilitation Centers segment dominates France Buprenorphine and Naloxone Market 2025 with 58.7% share, driven by medication-assisted treatment guidelines and relapse prevention demand.
- World-wide projected revenue of Indivior plc in fiscal year 2025 would be around $1.2 billion, owing to high demand for advanced opioid dependence treatments, long-acting buprenorphine formulations, and specialized behavioral therapy systems.
- It is expected that increasing modernization in retail pharmacy access, public funding needs in harm reduction programs, and adoption of digital patient adherence infrastructure would contribute in driving the growth of the market, where combination therapies offer misuse mitigation up to 41%, and minimize diversion errors up to 33%.
Download the eBook (ToC)
Why Buy This Report
- Gives an in-depth analysis of the impact of trends in medication-assisted treatment, expansion in community pharmacy distribution channels, and development in managed care reimbursement systems on the France Buprenorphine and Naloxone Market growth.
- Provides strategic insights regarding product innovation such as tamper-resistant sublingual matrices, film-coated therapeutic delivery technologies, smart digital compliance systems, and real-time electronic prescribing infrastructure.
- Assists players to analyze competitive benchmarking, investment in specialized psychiatric clinics, automation in public health distribution networks, and regional footprint expansion by major pharmaceutical manufacturers.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the France Buprenorphine and Naloxone Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in France Buprenorphine and Naloxone Market
- Indivior plc
- Camurus AB
- Ethypharm SAS
- Sublimed
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V. (Viatris Inc.)
- Accord Healthcare France
- Zentiva France
- Biogaran SAS
Recent Developments:
- In February 2026, Camurus AB expanded its supply agreement with French medical distributors to integrate advanced sublingual film options alongside its subcutaneous delivery networks, targeting improved care continuity in municipal substitution treatment units.
- In October 2025, Ethypharm SAS launched an updated buprenorphine/naloxone generic configuration with enhanced abuse-deterrent technologies optimized for domestic reimbursement guidelines and specialized psychiatric prescription workflows.
Market Segmentation:
France Buprenorphine and Naloxone Market, By Product Type
- Sublingual Films
- Sublingual Tablets
- Buccal Films
- Injectable Formulations
- Abuse-Deterrent Delivery Systems
France Buprenorphine and Naloxone Market, By Technology
- Tamper-Resistant Matrix Formulations
- Fast-Dissolving Polymer Networks
- Controlled-Release Drug Platforms
- Mucoadhesive Delivery Mechanics
- Microfluidic Bio-Sensing Architectures
France Buprenorphine and Naloxone Market, By Application
- Hospitals & Detoxification Clinics
- Outpatient Addiction Treatment Centers
- Community Pharmacies
- Government Rehabilitation Facilities
- Psychiatric Specialty Practices
Expert Views:
The market for buprenorphine and naloxone in France will grow owing to the rise in the demand for high efficacy substitution therapies, the growing number of modernization of public treatment clinics, and increasing demand for abuse-deterrent pharmaceutical variants. The inclusion of advanced tamper-resistant matrix technologies, digitized compliance monitoring configurations, and targeted clinical outreach protocols will enhance operational efficiency and boost the demand for buprenorphine and naloxone across the French pharmaceutical market.
Author: Aditi and Govind By Decisions Advisors and Consulting